Children with severe Osteogenesis imperfecta and short stature present on average with normal IGF-I and IGFBP-3 levels

被引:10
|
作者
Hoyer-Kuhn, Heike [1 ]
Hoebing, Laura [1 ]
Cassens, Julia [1 ]
Schoenau, Eckhard [1 ]
Semler, Oliver [1 ]
机构
[1] Univ Cologne, Childrens Hosp, Kerpenerstr 62, D-50937 Cologne, Germany
来源
关键词
IGF-I; Osteogenesis imperfecta; short stature; srowth hormone; GROWTH-HORMONE TREATMENT; BONE; ADOLESCENTS; THERAPY; HEIGHT; AXIS;
D O I
10.1515/jpem-2015-0385
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Osteogenesis imperfecta (OI) is characterized by bone fragility and short stature. Data about IGF-I/IGFBP-3 levels are rare in OI. Therefore IGF-I/IGFBP-3 levels in children with different types of OI were investigated. Methods: IGF-I and IGFBP-3 levels of 60 children (male n=38) were assessed in a retrospective cross-sectional setting. Results: Height/weight was significant different [height z-score type 3 versus type 4: p=0.0011 and weight (p <= 0.0001)] between OI type 3 and 4. Mean IGF-I levels were in the lower normal range (mean +/- SD level 137.4 +/- 109.1 mu g/L). Mean IGFBP-3 measurements were in the normal range (mean +/- SD 3.105 +/- 1.175 mg/L). No significant differences between OI type 3 and 4 children have been observed (IGF-I: p=0.0906; IGFBP-3: p=0.2042). Conclusions: Patients with different severities of OI have IGF-I and IGFBP-3 levels in the lower normal range. The type of OI does not significantly influence these growth factors.
引用
收藏
页码:813 / 818
页数:6
相关论文
共 50 条
  • [31] IGF-I and IGFBP-3 serum levels in patients hospitalized for complications of liver cirrhosis
    Ronsoni, Marcelo Fernando
    Lazzarotto, Cesar
    Fayad, Leonardo
    Silva, Mariana Costa
    Nogueira, Christiane Lourenco
    Bazzo, Maria Luiza
    Narciso-Schiavon, Janaina Luz
    Dantas-Correa, Esther Buzaglo
    Schiavon, Leonardo de Lucca
    ANNALS OF HEPATOLOGY, 2013, 12 (03) : 456 - 463
  • [32] Lack of Effect of Zinc Supplementation on Growth Velocity, Igf-I and Igfbp-3 in Normal Short Children. (Preliminar Communication) 26
    F Ugarte
    G Iniguez
    C Henriquez
    C Castillo
    T Salazar
    C Camacho
    F Beas
    A Avila
    T Capurro
    F Pizarro
    H Garcia
    Pediatric Research, 1998, 43 (2) : 299 - 299
  • [33] IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer
    Friedrichsen, DM
    Hawley, S
    Shu, J
    Humphrey, M
    Sabacan, L
    Iwasaki, L
    Etzioni, R
    Ostrander, EA
    Stanford, JL
    PROSTATE, 2005, 65 (01): : 44 - 51
  • [34] IGF-I and IGFBP-3 levels and their correlations with carcinoembryonic antigen in colorectal cancer patients
    Yucel, Cigdem Yagcioglu
    Erden, Gonul
    Yilmaz, Fatma Meric
    Sezer, Sevilay
    Calci, Esin
    ALEXANDRIA JOURNAL OF MEDICINE, 2018, 54 (01) : 11 - 15
  • [35] Race/ethnic variation in serum levels of IGF-I and IGFBP-3 in US adults
    Berrigan, David
    Potischman, Nancy
    Dodd, Kevin W.
    Hursting, Stephen D.
    Lavigne, Jackie
    Barrett, J. Carl
    Ballard-Barbash, Rachel
    GROWTH HORMONE & IGF RESEARCH, 2009, 19 (02) : 146 - 155
  • [36] IGF-I and IGFBP-3 during continuous and interval exercise
    Copeland, J. L.
    Heggie, L.
    INTERNATIONAL JOURNAL OF SPORTS MEDICINE, 2008, 29 (03) : 182 - 187
  • [37] Enhancement of IGF-I binding by IGFBP-3 at reduced pH
    Forsten, KE
    Akers, RM
    San Antonio, JD
    FASEB JOURNAL, 2001, 15 (05): : A757 - A757
  • [38] Increased levels of IGF-I and IGFBP-3 in synovial fluids of patients with rheumatoid arthritis
    Matsumoto, T
    Yamashita, S
    Rosenfeld, RG
    ENDOCRINE JOURNAL, 1998, 45 : S141 - S144
  • [39] Evaluation of serum IGF-I and IGFBP-3 on Nichols advantage
    Wang, S
    Ho, V
    CLINICAL CHEMISTRY, 2005, 51 : A224 - A224
  • [40] Reference values for IGF-I and IGFBP-3 serum concentrations
    Gonzalez Pereira, N.
    Tirado Uyuni, N. C.
    Cano Rodriguez, A.
    Pacheco Delgado, M.
    Sanchez Hernandez, C.
    Prieto Menchero, S.
    CLINICA CHIMICA ACTA, 2024, 558